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1. Introduction 
There are numerous reports describing cY-adrener- 
gic and cholinergic inhibition of CAMP accumulation 
in various tissues [ l-101 . The rat parotid gland pro- 
vides an excellent model system for the elucidation 
of inter-receptor interactions. The stimulation of 
a-adrenergic, /3-adrenergic and cholinergic-muscarinic 
receptors has been well characterized pharmacol- 
ogically, biochemically and morphologically and has 
been integrated into an overall scheme in [ 11 ,121. 
Cholinergic-muscarinic and a-adrenergic inhibition of 
CAMP accumulation, stimulated by activation of 
/3-adrenergic receptors in the rat parotid has been 
reported [13-IS]. Recent data from our laboratory 
demonstrated a different mechanism of action for the 
cholinergic and cu-adrenergic effect and also indicated 
adenylate cyclase as the target enzyme [ 16,171 . In 
the present communication we report a stable inhibi- 
tion of parotid adenylate cyclase in homogenates and 
washed membrane preparations following the ex- 
posure of tissue slices to carbamylcholine. 
2. Experimental methods 
Male Wistar rats (120-200 g) were used through- 
out. Rats were fasted overnight prior to sacrifice. The 
Abbreviations: CAMP, adenosine-3’,5’-monophosphate; 
EGTA, ethylene glycol-bis @-aminoethyl ether)-N,,N’-tetra- 
acetic acid; EDTA, ethylene diamine-N,N’-tetraacetic acid; 
PDE, phosphodiesterase 
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parotid slice incubation system was similar to that in 
[ 151, except that 10 mM /3-hydroxybutyrate was 
included in the Krebs-Ringer bicarbonate medium 
(KRB). Rat parotid homogenate was obtained by 
homogenizing slices which were decanted free of 
KRB in sucrose 0.3 M containing 5 mM ethylene 
glycol-bis @-aminoethyl ether)-Ar,hr’-tetra-acetic a id 
(EGTA) and 0.04 mM of ethylene diamine-N,N’- 
tetra-acetic acid (EDTA), pH 7.5 (sucrose medium) in 
a loose fitting Teflon-glass homogenizer (1 O-1 5 
strokes at 0-2°C). The homogenate was strained 
through nylon mesh to remove large particles. Crude 
particulate fraction was obtained by centrifuging the 
homogenate in a Beckman Microfuge for 5 min and 
resuspending the pellet in the original volume of 
sucrose medium. Hypotonically washed membranes 
were obtained by a procedure similar to that in [ 181 . 
Briefly, slices were homogenized in sucrose medium 
(l-2 ml/gland), centrifuged at 250 X g for 10 min at 
4°C and the pellet resuspended in (l-2 ml/gland) 
Tris-HCl 10 mM, EDTA 0.04 mM, MgClz 1 mM, 
pH 7.5 (Tris medium) by homogenization (5 strokes 
at 0-2°C). The suspension was centrifuged at 1500 X g 
for 10 min at 4°C and the cycle repeated one more 
time. The final pellet was resuspended in sucrose 
medium and strained through nylon mesh. The 
adenylate cyclase assay system consisted of Hepes 
(pH 7.5) 50 mM/[(r-32P]ATP 0.5 mM (lo-30 cpm/ 
pmol)/GTP 0.1 mM/cAMP 1 mM/MgCl* 10 mM/ 
EDTA 1 mM/RO 20-17241001 (CAMP phospho- 
diesterase inhibitor) 0.1 mM/phosphoenolpyruvate 
6 mM/pyruvate kinase 0.11 mg/ml/bovine serum 
albumin 0.1 mg/ml/various additions and homogenate 
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or membrane suspension in final vol. 0.1 ml. The 
reaction was initiated by the addition of adenylate 
cyclase preparation at 37°C and terminated by 
adding 0.8 ml solution of 0.25% sodium dodecyl 
sulphate-5 mM ATP (pH 7.5). The method in 
[ 191 was used for the separation of CAMP. Basal 
activity was assayed in the presence of 10 PM 
propranolol, and fluoride-stimulated activity in the 
presence of 10 mM KF. (-)-Isoproterenol, atropine, 
carbamylcholine and pyruvate kinase were obtained 
from Sigma, RO 20-1724/001 from Hoffman- 
LaRoche, [cY-‘~P]ATP from Amersham. All other 
chemicals were of analytical grade. 
3. Results 
The inclusion of CAMP (1 mM) and the PDE in- 
hibitor RO 20-l 724/001 in the adenylate cyclase 
assay system, each improved the assay of adenylate 
cyclase in parotid homogenates (fig.1). The reaction 
- 200 I- 
Time (min) 
1‘1g.1, The requirement for cAMP and cAMP phosphodiester- 
ase mhibttor in adenylate cyclasc assay in parotid homoge- 
nates. Rat parotid glands were excised and incubated in KRB 
as in section 2. At the end of the incubation. slices were 
pelleted by rdpid centrifugation (1500 X g, 30 min), the 
KRB was aspirated and the tissue homogenized in sucrose 
medium (0.5 ml/gland). The homogenate was strained 
through nylon mesh and assayed for adenyiate cyclase ac- 
tivity in the presence of 1 mM cAhlP and 0.1 mM RO 20- 
1724 (complete), without CAMP, or without CAMP and 
RO 20-1724 in the presence of (G)-isoproterenol (20 MM). 
was not linear with time and short incubation times 
were required. GTP (0.1 mM) in the assay system 
dramatlcally improved the basal and (-)-isoprotere- 
nol-stimulated activities (4-7-fold, not shown) with- 
out affecting the fluoride-stimulated activity. This 
resulted in an improved ratio of (-)-isoproterenol- 
stimulated and fluoride-stimulated activities. 
(-)-Isoproterenol-stimulated adenylate cyclase 
activity was inhibited in homogenates prepared from 
carbamylcholine-treated slices. Basal and fluoride 
activities were unaffected. The (-)-isoproterenol 
inhibition was larger in hypotonically-washed mem- 
branes. The basal and fluoride activities in washed 
membranes were inhibited, albeit less than the (-)- 
isoproterenol-stimulated activities (table 1). Although 
the activities in the absence of CAMP and the PDE 
inhibitor in the assay system were lower, their ab- 
sence did not affect the inhibition of (-)-isopro- 
terenol-stimulated activity caused by carbamylcholine 
in the homogenate (table 2). Atropine (20 PM) added 
before carbamylcholine (35 PM) abolished the inhibi- 
tion of adenylate cyclase in washed membranes (table 
3). Membranes stored at -20°C in sucrose medium 
preserved their activity and the carbamylcholine 
inhibition (not shown). The addition of carbamyl- 
choline to homogenization medium, Tris medium or 
assay system did not result in higher inhibition (not 
shown). When control membranes or membranes 
Table 1 
Adenylate cyclase inhibition in homogenates and 
washed membranes 
--- __________ 
Inhibition of adenylate cyclase activity (a) 
Homogenate Washed membranes 
--__ 
Basal PO.5 + 4.1 21.0 + 3.3 
(-)-Isoproterenol 
20 /.IM 28.0 c 4.9 50.2 t 3.4 
Fluoride 
10 mM -0.2 + 7.1 27.7 + 6.5 
~____ 
Parotid slices were incubated as in section 2 with and without 
carbamylcholine (50 wM, 18 min). Homogenates and washed 
membranes were prepared as in section 2. Reaction time was 
l-3 min in homogenates and 10 min in washed membranes. 
The results are mean k SEM of 6 individual experiments. 
(-)-Isoproterenol-stimulated and tluoride-stimulated activi- 
ties were calculated as net increases after subtraction of basal 
activities 
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Table 2 
Cholinergic inhibition of adenylate cyclase in homogenates 
in the presence and the absence of CAMP and PDE 
inhibitor (pmol cAMP/mg protein X min) 
_____ 
Control Carbamylcholine 
Additions None CAMP None CAMP 
RO 20-I 724 RO 20-l 724 
Basal 3.1 5.4 1.6 5.3 
(-)-Isoproterenol 
20 /.LM 10.8 29.6 8.3 22.1 
Fluoride 
10 miM 8.6 21.2 8.5 21.1 
____ 
Homogenates of control and carbamylcholine-treated parotid 
slices (50 PM, 18 min) were prepared as in section 2. Homo- 
genates were assayed for adenylate cyclase activity with and 
without cAIMP (1 mrM) and RO 20-1724/001 (0.1 mlM) for 
1.5 min. Basal activities were subtracted from (-)-isoprote- 
renal-stimulated and fluoride-stimulated activities 
derived from slices pre-exposed to carbamylcholine 
were challenged with increasing concentrations of 
(-)-isoproterenol the resulting dose-response curves 
were similar in shape with lower Pm, for the car- 
bamylcholine-treated membranes (fig.2) and indicated 
either negative cooperativity or two different popula- 
tions of adenylate cyclase-receptor systems (fig.2, 
inset). 
Table 3 
IMuscarinic blocking of cholinergic inhibition of 
adenylate cyclase 
Control Carbamyl- Carbamylcholine 
choline + atropine 
Basal 55.5 41.8 50.4 
(-)-Isoproterenol 
20 PM 
Fluoride 
229.1 98.4 193.4 
10 mM 319.6 188.6 295.4 
Parotid slices were incubated for 19 min in KRB. Atropine 
(20 PM) was added to one system at zero time followed 
1 min later by carbamylcholine (35 PM). Washed membranes 
were prepared as in section 2 and assayed for adenylate cy- 
clase activity for 10 min. Basal activities were subtracted 
from (-)-isoproterenol-stimulated and fluoride-stimulated 
activities 
Fig.2. Dose response to (-)-isoproterenol in washed mem- 
branes. Parotid slices were treated with carbamylcholine 
(50 PM) for 18 min. The incubation was terminated by 
pelleting the tissue and aspirating the medium. Washed 
membranes were prepared as in section 2. The membrane 
protein (0.16 mg) was incubated in the adenylate cyclase 
assay system for 10 min. Basal activities in the presence of 
10 PM propranolol were subtracted from (-)-isoproterenol- 
stimulated activities (30.9 pmol/mg X min for control mem- 
branes, 22.2 pmol/mg x min for carbamylcholine-treated 
membranes). (o-0) Control; (o---o) carbamylcholine. 
4. Discussion 
The rat parotid provides a model system for the 
interaction between different neurotransmitter recep- 
tors in the same cell. Until recently those interactions 
could be analyzed by indirect evidence derived from 
the modification of cell physiology or changes in 
concentrations of various compounds in the whole 
cell (e.g., CAMP concentration changes in rat 
parotid). Obviously, this precludes a direct approach 
to the elucidation of the molecular mechanisms 
involved. 
We have recently reported that a-adrenergic and 
cholinergic-muscarinic stimulation modulate CAMP 
concentrations in the rat parotid [ 16,171 . Indirect 
evidence obtained from tissue-slice experiments 
suggest he adenylate cyclase as the target enzyme. 
The present report supports this conclusion in the 
case of the cholinergic-muscarinic receptor. 
Tissue slices exposed to carbamylcholine exhibited 
inhibition of adenylate cyclase activity in homo- 
genates and washed membranes. The inhibition was 
333 
Volume 94, number 2 I‘EBS LETTERS October 1978 
unaffected by the omission of CAMP and PDE 
inhibitor from the assay system. Moreover, basal and 
fluoride-stimulated activities were inhibited to a 
smaller extent than the (-)-isoproterenol-stimulated 
activity. All of these eliminate the PDE as the target 
enzyme. It is possible that the exposure of parotid 
slices to carbamylcholine affects the stability of 
adenylate cyclase in addition to the inhibition of the 
(-)-isoproterenol-stimulated activity. The inhibition 
is expressed in washed membrane preparations either 
due to the effects of the isolation procedure, or due 
to the removal of a protecting agent(s) present in the 
homogenate. We are currently investigating these 
possibilities. 
Dose-response curves to (-)-isoproterenol indi- 
cate that similar concentrations of (-)-isoproterenol 
will produce half-maximal stimulation in both control 
and carbamylcholine-treated membranes. The dose- 
response curves were non-hyperbolic and indicated 
negative cooperativity or, alternatively, two subpopu- 
lations of the receptor-linked adenylate cyclase. We 
have recently reported a similar phenomenon in the 
stimulation of CAMP concentrations in response to 
(-)-isoproterenol in parotid slices [ 171 . The inhibi- 
tion appeared to be cholinergic-muscarinic, since the 
addition of atropine to the slices abolished the effect 
of carbamylcholine. The cholinergic inhibition was 
stable to both purification procedures and storage at 
-20°C over an extended period of time. 
The development of a system exhibiting a stable 
inhibition of a relatively well-characterized enzyme 
opens the way for a systematic study of the molec- 
ular mechanisms involved. A cholinergic inhibition 
of cardiac adenylate cyclase was reported in 1962 
[20] . A cholinergic-muscarinic inhibition of ade- 
nylate cyclase in cardiac sarcolemma has recently been 
reported [2 1 ] . It appears that the guanine-nucleotide 
regulatory site is affected in their preparation. We are 
currently investigating the influence of cholinergic 
stimulation on the kinetic and binding properties of 
the /I-adrenergic receptor in rat parotid. 
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